Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
September 09 2020 - 4:01PM
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical
company, today announced that it has commenced an underwritten
public offering of $350 million of shares of its common stock. In
connection with the offering, Intra-Cellular Therapies intends to
grant the underwriters a 30-day option to purchase up to an
additional 15% of the shares of common stock offered in the public
offering. All of the shares in the offering will be sold by
Intra-Cellular Therapies.
J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, SVB
Leerink LLC and Evercore Group L.L.C. are acting as joint
book-running managers for the offering. The offering is subject to
market and other conditions, and there can be no assurance as to
whether or when the offering may be completed, or as to the actual
size or terms of the offering.
The public offering will be made pursuant to a shelf
registration statement on Form S-3 that was previously filed with
the Securities and Exchange Commission (the “SEC”) and became
effective upon filing. A preliminary prospectus supplement and
accompanying base prospectus relating to and describing the terms
of the offering will be filed with the SEC and will be available on
the SEC’s website located at http://www.sec.gov. The offering
is being made only by means of a prospectus and related prospectus
supplement, copies of which may be obtained from J.P. Morgan
Securities LLC, Attention: Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717, by telephone at
1-866-803-9204, or by email at prospectus-eq_fi@jpmchase.com,
Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200
West Street, New York, NY 10282, by telephone at 1-866-471-2526, or
by email at prospectus-ny@ny.email.gs.com, SVB Leerink LLC,
Attention: Syndicate Department, One Federal Street, 37th Floor,
Boston, MA 02110, by telephone at 1-800-808-7525, ext. 6132, or by
email at syndicate@svbleerink.com, or Evercore Group L.L.C.,
Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor,
New York, NY 10055, by telephone at (888) 474-0200, or by email at
ecm.prospectus@evercore.com. The final terms of the offering will
be disclosed in a final prospectus supplement to be filed with the
SEC.
This press release shall not constitute an offer to sell, or a
solicitation of an offer to buy, nor will there be any sale of
these securities in any state or other jurisdiction in which such
an offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or other jurisdiction.
About Intra-Cellular Therapies
Intra-Cellular Therapies is a biopharmaceutical company founded
on Nobel prize-winning research that allows us to understand how
therapies affect the inner-workings of cells in the body. The
company leverages this intracellular approach to develop innovative
treatments for people living with complex psychiatric and
neurologic diseases.
Forward-Looking Statements
This press release includes “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements include statements, other than
statements of historical fact, regarding, among other things, the
proposed public offering of common stock. Intra-Cellular Therapies
often uses words such as “anticipates,” “believes,” “plans,”
“expects,” “projects,” “future,” “intends,” “may,” “will,”
“should,” “could,” “estimates,” “predicts,” “potential,” “planned,”
“continue,” “guidance,” and similar expressions to identify
forward-looking statements. Actual results, performance or
experience may differ materially from those expressed or implied by
any forward-looking statement as a result of various risks,
uncertainties and other factors, including, but not limited to:
uncertainties related to market conditions and the completion of
the public offering on the anticipated terms or at all, and other
risks and uncertainties that are described under the heading “Risk
Factors” in Intra-Cellular Therapies’ preliminary prospectus
supplement to be filed with the SEC, Intra-Cellular Therapies’ most
recent Annual Report on Form 10-K or in subsequent filings that it
makes with the Securities and Exchange Commission. As a result of
risks and uncertainties that Intra-Cellular Therapies faces, the
results or events indicated by any forward-looking statement may
not occur. Intra-Cellular Therapies cautions you not to place undue
reliance on any forward-looking statement. In addition, any
forward-looking statement in this press release represents
Intra-Cellular Therapies’ views only as of the date of this press
release and should not be relied upon as representing its views as
of any subsequent date. Intra-Cellular Therapies disclaims any
obligation to update any forward-looking statement, except as
required by applicable law.
Contact
Intra-Cellular Therapies, Inc.Juan Sanchez, M.D.Vice President,
Corporate Communications and Investor Relations646-440-9333
Burns McClellan, Inc. Lisa Burns jgrimaldi@burnsmc.com
212-213-0006
Media Inquiries:
Ana FullmerCorporate Media Relations
W20wcgafullmer@wcgworld.com202-507-0130
Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
From Apr 2023 to Apr 2024